Aug 2026· Cancer Genetics· Vol 308-309, pp.
15-29
· 0 citations· 39 references
Medicine
TL;DR
The results identify eIF3A as a key regulator of CC progression in an m6A-dependent ENO1 translation and suggest that targeting the eIF3A-m6A-ENO1 may have therapeutic potential for CC.
Abstract
Eukaryotic translation initiation factors (eIFs) play a crucial role in tumor progression; however, which eIFs are most significant in cervical cancer (CC) remains unclear. In this study, eIF3A and eIF4E were found to be highly expressed in CC and associated with poor prognosis. Silencing either factor inhibited CC cell proliferation, induced apoptosis, and reduced glycolytic activity. Quantitative proteomic analysis and subsequent functional validation identified α-enolase (ENO1) as a common downstream effector of eIF3A and eIF4E, through which they promoted aerobic glycolysis and CC progression. Notably, eIF3A consistently exhibited a more pronounced functional effect than eIF4E. Further analyses demonstrated that eIF3A associated with N6-methyladenosine (m6A)-modified ENO1 mRNA and promoted its translation. eIF3A depletion reduced the abundance of ENO1 mRNA in actively translating polysomes and decreased the ENO1 protein-to-mRNA ratio without affecting total ENO1 mRNA abundance. Mutation of a key m6A site A359 in ENO1 mRNA similarly weakened its association with eIF3A and reduced ENO1 translation. Moreover, pharmacological inhibition of m6A-related regulation partially attenuated eIF3A-induced ENO1 expression, glycolytic activation, and tumor growth. Collectively, our results identify eIF3A as a key regulator of CC progression in an m6A-dependent ENO1 translation and suggest that targeting the eIF3A-m6A-ENO1 may have therapeutic potential for CC.
Clinically, high expression of eIF4A1, p70S6K, and TCF7L2 correlates with unfavorable prognosis in GC patients, and findings highlight eIF4A1 as a key regulator of stemness and metastasis through a novel translational feedback mechanism, suggesting potential therapeutic targeting to disrupt tumor progression.
Xiangyu Su, Yingming Zhu, Xuemin Song et al.· Biochemical Pharmacology· 0 citations
Integrated transcriptomic and translatomic profiling demonstrated that this axis orchestrated extensive reprogramming of mRNA metabolism, ribosome biogenesis and cancer-associated signaling pathways, underscoring its multilayered role in tumor progression.
Sha Yang, Zhen Shang, Shun-Xiang Xia et al.· International Journal of Onc...· 0 citations
Mechanistic investigations demonstrated that NAT10 elevates MARK2 expression, activating the mTOR/HIF-1α/C-Myc signaling cascade, thereby promoting aerobic glycolysis in PCa cells, suggesting that targeting ac4C mRNA modifications may provide a novel therapeutic strategy for managing prostate cancer.
Yi-Ming Zhang, Jian Wang, Gan-Ping Wang et al.· Cancer Gene Therapy· 0 citations
It is revealed that BYSL acts as a pivotal downstream mediator of MYC-regulated ribosome biogenesis and promotes hepatocellular carcinoma progression, suggesting that BYSL may represent a potential therapeutic target for hepatocellular carcinoma.
Heyuan Zhao, Hui-Ying Liu, Xia Liu et al.· Cellular Signalling· 0 citations
EIF2S1 is associated with adverse prognosis, translation initiation-related programs, and monocyte-like immune-metabolic transcriptional states in AML, and functional findings suggest that EIF2S1 contributes to leukemic cell fitness.
Xiaoying Hong, Yingying Huang, Wei Wu et al.· Frontiers in Oncology· 0 citations
It is demonstrated that IGF2BP1 drives GC progression by stabilizing HS6ST2 mRNA via m6A modification and the IGF2BP1/HS6ST2 axis may serve as a potential prognostic biomarker and therapeutic intervention for GC.
Lu Liu, Yi-jing Zhou, Yue Xu et al.· World Journal of Gastrointes...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.